Use of selected CD34+ cells in the treatment of relapsed/progressive HD: experiences from a single center

Cytotherapy. 2002;4(2):177-80. doi: 10.1080/146532402317381884.

Abstract

Background: Treatment of HD using positively selected stem cells can achieve a durable CR in almost 80% patients, with a median follow-up of 24 months. We have found the use of positive selected CD34+ cells in the treatment of relapsed/progressive HD after high-dose chemotherapy to be a safe procedure with promising results.

Methods: Positively selected (CD34+) stem cells were employed for autografting in the patients with HD after high-dose chemotherapy.

Results: Between April 1996 and February 2001, 28 patients with relapsed/progressive HD were autografted with positively selected CD34+ cells at our Institute. All patients are alive and we did not observe any deaths as a result of toxicity. From this group, 22 (78.6%) patients are in durable CR, with a median follow-up of 24 months (range 7-65 months). Six (21.4%) patients relapsed but are now in CR after radiotherapy and mini-allogeneic transplantation (one patient) or radiotherapy (five patients).

Discussion: Autologous transplantation with positively selected CD34+ cells in relapsed HD is a safe and effective procedure in the treatment of this disease.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antigens, CD34 / immunology*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hematopoietic Stem Cells / immunology*
  • Hodgkin Disease / therapy*
  • Humans
  • Male
  • Middle Aged
  • Transplantation, Autologous

Substances

  • Antigens, CD34